Clinical trial · Interventional
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
Effects of Aspirin on Platelet Function and Clinical Outcome in Patients With Thrombocytopenia, Neoplasm, and Myocardial Infarction
NCT00501345CI-TRIAL-00007676terminatedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual, study terminated.
Summary
Brief summary (as posted)
Primary Objective: To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well as platelet functions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myocardial Infarction | — | UNRESOLVED | — |
| Thrombocytopenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aspirin | Drug | Aspirin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Aspirin
- interventionNames
- Drug: Aspirin
Primary outcomes (1)
- measure
- Participants With 7 Days Observation Without Severe Bleeding
- timeFrame
- 7 Days
- description
- Blood samples collected at baseline before or after aspirin is given and at 24 hours, 72 hours and 7 days after treatment has been initiated for those that remain in the study after the first 24 hours.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Presenting for Cardiology consult at M.D. Anderson Cancer Center. 2. Platelet count between 100,000 and 20,000. 3. Acute Coronary Syndrome diagnosed with their first 12 lead EKG. 4. Patients that continue to show evidence of MI by cardiac enzymes with CPK levels \> 2 normal limits, CK-MB levels 10% above normal limits, and Troponin I levels \> 1.4ug/L will be considered positive for MI. 5. Ability to give consent. Exclusion Criteria: 1. Contraindications to aspirin including severe intolerance or true allergy, active bleeding, hemophilia, active retinal bleeding, severe untreated hypertension, active peptic ulcer, or other significant source of gastrointestinal or genitourinary bleeding, brain metastasis, and altered mental status. 2. Unwillingness or inability to give consent. 3. Progressive heart failure, unstable angina not responding to medical therapy for 24 hours, or ventricular tachycardia, necessitating thrombolysis, and angioplasty. 4. Patients that rule out for MI by cardiac enzymes panel after the first 24 hours. 5. Patients that rule in for MI and have Platelet count \> 100,000. 6. Patients with platelet count \< 20,000.
References
Publications (0)
Data not yet available
No reference posted for this study.